Recent studies have suggested that NaV1.7 plays a role in visceral hypersensitivity of IBS, and, therefore, NaV1.7 inhibitors could be a viable treatment option to treat chronic visceral pain in IBS [39]. Here, SCN9A is linked to irritable bowel syndrome.